1. Home
  2. CMCO vs ANL Comparison

CMCO vs ANL Comparison

Compare CMCO & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Columbus McKinnon Corporation

CMCO

Columbus McKinnon Corporation

HOLD

Current Price

$17.84

Market Cap

555.6M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$14.57

Market Cap

611.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCO
ANL
Founded
1875
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
555.6M
611.1M
IPO Year
2002
2022

Fundamental Metrics

Financial Performance
Metric
CMCO
ANL
Price
$17.84
$14.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$21.00
$20.00
AVG Volume (30 Days)
718.9K
160.4K
Earning Date
05-27-2026
04-10-2026
Dividend Yield
1.90%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$936,240,000.00
N/A
Revenue This Year
$19.73
$36.02
Revenue Next Year
$82.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.27
N/A
52 Week Low
$11.99
$0.88
52 Week High
$24.40
$17.25

Technical Indicators

Market Signals
Indicator
CMCO
ANL
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CMCO
ANL

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a world-wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Its key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements. The company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: